Abstract 143: Effects of Long-Term Administration of Dexmedetomidine on Inflammatory Responses in Patients with Severe Sepsis
Background: Several studies showed that dexmedetomidine (DEX), a new sedative and alpha-2 adrenoceptor agonist, drastically inhibited the inflammatory responses in septic animals. Moreover, DEX was recently reported to attenuate the elevation of pro-inflammatory cytokines in septic patients. However, there are few studies about the effects of long-term administration of DEX in severe septic patients. The present study evaluated the effects of long-term administration of DEX on inflammatory responses in severe septic patients.
Hypothesis: We hypothesis that the long-term administration of DEX has beneficial effects for severe septic patients.
Methods: Twenty-one patients (M/F 13/8, mean age 54 years) with severe sepsis, who were administered propofol (0.5-4.0 mg/kg/hr) only for sedation, were administered DEX (0.4-1.0 ug/kg/hr) more than 24 hours in addition to propofol. Primary outcome were changes in inflammatory responses at 48hrs after the administration of DEX, and secondary outcome was change in SOFA scores at 48hrs after the administration of DEX.
Results: The administration of DEX underwent for mean 154 hours (24-433 hours). WBC counts, CRP and PCT significantly decreased after the administration of DEX (WBC 10400 ± 6900 vs 6600 ± 3500 /uL; p<0.05, CRP 14.6 ± 8.0 vs 6.6 ± 6.5 mg/dL; p<0.05, PCT 11.6 ± 11.6 vs 3.6 ± 6.6 ng/mL; p<0.05). SOFA score decreased after the administration of DEX (10.1 vs 7.1; p<0.05). All patients recovered and discharged in ICU.
Conclusion: In the present study, the long-term administration of DEX has beneficial effects of inflammatory responses for severe septic patients.
- © 2011 by American Heart Association, Inc.